Insiya B. Poonawalla
Research Subjects
Research Interests
Insiya B. Poonawalla has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Darla E. Kendzor
TSET Health Promotion Research Center, University of Oklahoma Health Campus, Oklahoma City, OK, United States
3 shared publications - Andy Bowe
Louisville, Ky
2 shared publications - David W. Wetter
Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, United States
2 shared publications - Erica L. Cuate
School of Public Health University of Texas Health Science Center Dallas, TX United States
2 shared publications - Jeffrey J. Ellis
US VEO, GSK, Collegeville, USA
2 shared publications - Michael S. Businelle
University of Oklahoma Health Campus and Stephenson Cancer Center, OK, USA
2 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (8)
Association between integrated specialty pharmacy care model and pharmaceutical access and costs
Introduction: Health care consolidation in the United States has yielded mixed outcomes for patients; however, little is known about the impact of integration between insurers and specialty pharmacies. Through improved data and clinical integration, integrated specialty pharmacy care models may improve health care access and reduce costs for beneficiaries. However, this type of vertical integration may allow increased market power, which could lead to higher costs for beneficiaries. Methods: Using Humana prescription claims, our cross-sectional study used adjusted regression analyses evaluating the association between the use of an integrated specialty pharmacy care model with pharmaceutical access and costs for beneficiaries managing complex specialty conditions in 2024. Results: After adjusting for demographic and clinical characteristics, the integrated specialty pharmacy care model was associated with fewer days from prescription to fill (absolute difference: −5.7 days; 95% CI: −6.7 to −4.7 days) and, reduced yearly beneficiary pharmacy costs (−$106; 95% CI: −$163 to −$49) and yearly beneficiary costs for the specialty drug (−$77; 95% CI: −$129 to −$27) compared with nonintegrated specialty pharmacies. We found additional benefits for beneficiaries who also used integrated primary care services. Conclusion: Integrated specialty pharmacy care models may deliver faster and less costly pharmaceutical care for beneficiaries.
- 23 July 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (8)
Open AccessAssociation between integrated specialty pharmacy care model and pharmaceutical access and costs
Introduction: Health care consolidation in the United States has yielded mixed outcomes for patients; however, little is known about the impact of integration between insurers and specialty pharmacies. Through improved data and clinical integration, integrated specialty pharmacy care models may improve health care access and reduce costs for beneficiaries. However, this type of vertical integration may allow increased market power, which could lead to higher costs for beneficiaries. Methods: Using Humana prescription claims, our cross-sectional study used adjusted regression analyses evaluating the association between the use of an integrated specialty pharmacy care model with pharmaceutical access and costs for beneficiaries managing complex specialty conditions in 2024. Results: After adjusting for demographic and clinical characteristics, the integrated specialty pharmacy care model was associated with fewer days from prescription to fill (absolute difference: −5.7 days; 95% CI: −6.7 to −4.7 days) and, reduced yearly beneficiary pharmacy costs (−$106; 95% CI: −$163 to −$49) and yearly beneficiary costs for the specialty drug (−$77; 95% CI: −$129 to −$27) compared with nonintegrated specialty pharmacies. We found additional benefits for beneficiaries who also used integrated primary care services. Conclusion: Integrated specialty pharmacy care models may deliver faster and less costly pharmaceutical care for beneficiaries.
- 1 July 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (5) , 1566-1573.e1
Home versus outpatient hospital intravenous immunoglobulin infusion and health care resource utilization
- 1 July 2023
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (5) , 1566-1573.e1
Home versus outpatient hospital intravenous immunoglobulin infusion and health care resource utilization
- Open Access
- 1 April 2023
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 29 (4) , 350-356
Early vs late filling of new heart failure prescription and its association with avoidable hospital admissions
BACKGROUND: Individuals with heart failure (HF) are at increased risk for hospitalization and readmission after discharge. The impact of timing to new prescription filling on avoidable HF hospitalization is understudied in HF management. The Agency of Healthcare Research and Quality identifies HF-related inpatient admissions as potentially avoidable if they could be managed successfully in outpatient settings. OBJECTIVE: To compare avoidable HF hospitalization rate and all-cause and HF-related costs in patients who were early fillers (≤30 days) vs late fillers (>30 days) of newly prescribed HF medications following an HF-related inpatient stay or emergency department visit. METHODS: This retrospective cohort study used the Humana Research Database to identify patients with at least 1 claim for a new HF medication from January 1, 2018, to June 30, 2019. Eligible patients were enrolled in a Medicare Advantage Prescription Drug plan for at least 12 months pre-index and 6-months post-index (ie, first new HF prescription). Individuals who were early (n = 794) vs late fillers (n = 397) were propensity-score matched in a 2:1 ratio to balance baseline characteristics. A logistic regression model was fitted to compare avoidable HF hospitalization in those who were late fillers vs early fillers. Mean cost differences were compared using paired t-test. Outcomes were measured 6-months post-index. RESULTS: Late fillers had greater odds of experiencing an avoidable HF hospitalization compared with early fillers (odds ratio = 1.65; P = 0.001). Late filling was associated with a 49.5% increase in average all-cause medical costs (P < 0.0001), a 13.6% decrease in average all-cause pharmacy costs (P = 0.0929), and a 39.4% increase in average all-cause total costs (P < 0.0001). HF-related costs showed similar trends. CONCLUSION: Compared with patients who filled their prescription within 30 days of discharge following an HF admission, those who delayed the filling of a new HF prescription experienced increased likelihood of an avoidable readmission, and late filling was associated with increased 6-month total and medical costs. DISCLOSURES: Humana Healthcare Research, Inc., funded the research and article development. No external funds were used in the creation of this work. All authors are/were employees of Humana Inc. and/or Humana Healthcare Research, Inc., at the time of the work.
- 1 April 2023
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 29 (4) , 350-356
Open AccessEarly vs late filling of new heart failure prescription and its association with avoidable hospital admissions
BACKGROUND: Individuals with heart failure (HF) are at increased risk for hospitalization and readmission after discharge. The impact of timing to new prescription filling on avoidable HF hospitalization is understudied in HF management. The Agency of Healthcare Research and Quality identifies HF-related inpatient admissions as potentially avoidable if they could be managed successfully in outpatient settings. OBJECTIVE: To compare avoidable HF hospitalization rate and all-cause and HF-related costs in patients who were early fillers (≤30 days) vs late fillers (>30 days) of newly prescribed HF medications following an HF-related inpatient stay or emergency department visit. METHODS: This retrospective cohort study used the Humana Research Database to identify patients with at least 1 claim for a new HF medication from January 1, 2018, to June 30, 2019. Eligible patients were enrolled in a Medicare Advantage Prescription Drug plan for at least 12 months pre-index and 6-months post-index (ie, first new HF prescription). Individuals who were early (n = 794) vs late fillers (n = 397) were propensity-score matched in a 2:1 ratio to balance baseline characteristics. A logistic regression model was fitted to compare avoidable HF hospitalization in those who were late fillers vs early fillers. Mean cost differences were compared using paired t-test. Outcomes were measured 6-months post-index. RESULTS: Late fillers had greater odds of experiencing an avoidable HF hospitalization compared with early fillers (odds ratio = 1.65; P = 0.001). Late filling was associated with a 49.5% increase in average all-cause medical costs (P < 0.0001), a 13.6% decrease in average all-cause pharmacy costs (P = 0.0929), and a 39.4% increase in average all-cause total costs (P < 0.0001). HF-related costs showed similar trends. CONCLUSION: Compared with patients who filled their prescription within 30 days of discharge following an HF admission, those who delayed the filling of a new HF prescription experienced increased likelihood of an avoidable readmission, and late filling was associated with increased 6-month total and medical costs. DISCLOSURES: Humana Healthcare Research, Inc., funded the research and article development. No external funds were used in the creation of this work. All authors are/were employees of Humana Inc. and/or Humana Healthcare Research, Inc., at the time of the work.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
1428-P: Cardiovascular Outcomes with Dulaglutide vs. Liraglutide
While emerging evidence shows cardiovascular (CV) benefits associated with use of specific glucagon-like peptide-1 (GLP-1) agonists, there is limited data on how outcomes compare between agents in the same drug class. This retrospective cohort study compared once-weekly dulaglutide and once-daily liraglutide on CV outcomes, treatment persistence/discontinuation, healthcare utilization and costs. Using administrative claims data from a large commercial and Medicare Advantage Prescription Drug health plan, new users of liraglutide or dulaglutide from January 2015 to June 2017 were identified. Eligible patients were 19-89 years, with at least 12 months of continuous enrollment pre- and post-index date (i.e., date of first new prescription). Patients who had prescription claims for other GLP-1 agonists were excluded. Propensity score matching (1:1) resulted in 2,245 patients in each treatment arm. The risk of primary composite CV outcome (myocardial infarction [MI] or stroke or mortality) and secondary CV outcome (heart failure [HF] or mortality) was similar across treatment groups, but patients indexed to dulaglutide were less likely to encounter a MI (relative risk [RR] 0.80, P=0.028) or HF (RR 0.81, P=0.001) event. Treatment discontinuation was lower in patients who used dulaglutide vs. liraglutide (57.8% vs. 63.2%, P<0.0001; hazard ratio 0.85, 95% confidence interval 0.79-0.92). The average per-person per-month pharmacy cost was higher for dulaglutide compared to the liraglutide cohort ($1,027 vs. 954, P=0.047). Total and medical costs, inpatient hospitalization stays, emergency department visits and outpatient service visits were similar across cohorts. Despite a lack of significant effect on the study’s composite CV outcomes, this real-world study showed longer treatment persistence with the use of dulaglutide that may be associated with lower MI and HF events. Findings may be useful to providers, especially in the treatment of patients who prefer once-weekly versus once-daily subcutaneous injection. Disclosure: A. Bowe: Employee; Self; Humana. I. Poonawalla: None. M. Tindal: None. Y.A. Meah: None. P. Schwab: Employee; Self; Humana. Employee; Spouse/Partner; Humana.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
1428-P: Cardiovascular Outcomes with Dulaglutide vs. Liraglutide
While emerging evidence shows cardiovascular (CV) benefits associated with use of specific glucagon-like peptide-1 (GLP-1) agonists, there is limited data on how outcomes compare between agents in the same drug class. This retrospective cohort study compared once-weekly dulaglutide and once-daily liraglutide on CV outcomes, treatment persistence/discontinuation, healthcare utilization and costs. Using administrative claims data from a large commercial and Medicare Advantage Prescription Drug health plan, new users of liraglutide or dulaglutide from January 2015 to June 2017 were identified. Eligible patients were 19-89 years, with at least 12 months of continuous enrollment pre- and post-index date (i.e., date of first new prescription). Patients who had prescription claims for other GLP-1 agonists were excluded. Propensity score matching (1:1) resulted in 2,245 patients in each treatment arm. The risk of primary composite CV outcome (myocardial infarction [MI] or stroke or mortality) and secondary CV outcome (heart failure [HF] or mortality) was similar across treatment groups, but patients indexed to dulaglutide were less likely to encounter a MI (relative risk [RR] 0.80, P=0.028) or HF (RR 0.81, P=0.001) event. Treatment discontinuation was lower in patients who used dulaglutide vs. liraglutide (57.8% vs. 63.2%, P<0.0001; hazard ratio 0.85, 95% confidence interval 0.79-0.92). The average per-person per-month pharmacy cost was higher for dulaglutide compared to the liraglutide cohort ($1,027 vs. 954, P=0.047). Total and medical costs, inpatient hospitalization stays, emergency department visits and outpatient service visits were similar across cohorts. Despite a lack of significant effect on the study’s composite CV outcomes, this real-world study showed longer treatment persistence with the use of dulaglutide that may be associated with lower MI and HF events. Findings may be useful to providers, especially in the treatment of patients who prefer once-weekly versus once-daily subcutaneous injection. Disclosure: A. Bowe: Employee; Self; Humana. I. Poonawalla: None. M. Tindal: None. Y.A. Meah: None. P. Schwab: Employee; Self; Humana. Employee; Spouse/Partner; Humana.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
36-OR: Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists
This retrospective cohort study compared sodium-glucose co-transporter-2 (SGLT2) inhibitor and glucagon-like peptide-1 (GLP-1) agonist therapeutic drug classes on cardiovascular (CV) outcomes, treatment persistence/discontinuation, healthcare utilization and costs. Using medical and pharmacy claims data from the Humana Research Database, new users of SGLT2 inhibitors or GLP-1 agonists from January 2015 to June 2017 were identified. Eligible patients were 19-89 years, enrolled in a Medicare Advantage Prescription Drug or fully-insured commercial health plan, with at least 12 months of continuous enrollment pre- and post-index date (i.e., date of first new prescription). Propensity score matching (1:1) was used to balance baseline characteristics. Cox proportional hazards models were used to compare CV outcomes and treatment discontinuation. Healthcare resource utilization and costs were compared using Wilcoxon signed rank test. A total of 5,507 patients were included in each treatment group. Patients indexed to use GLP-1 agonists were more likely to discontinue treatment (hazard ratio 1.15, 95% confidence interval 1.10-1.21) and more likely to encounter an inpatient hospitalization (14.4% vs. 11.9%, P<0.001) or emergency department visit (27.4% vs. 23.5%, P <0.001) compared to patients indexed on SGLT2 inhibitors. The risk of primary composite CV outcome (myocardial infarction or stroke or mortality) and secondary CV outcome (heart failure or death) was similar across cohorts. The average per-person per-month total cost ($1,796 vs. $1,617, P<0.001), medical ($904 vs. $834, P<0.001) and pharmacy costs ($891 vs. $783, P<0.001) were higher for the GLP-1 agonist cohort compared to the SGLT2 inhibitor cohort. Although differences in extra-glycemic CV benefits were not established, these findings may be useful to providers and payers, as this real-world data showed SGLT2 inhibitors were associated with longer treatment persistence and reduced healthcare utilization and costs relative to GLP-1 agonists. Disclosure: I. Poonawalla: None. A. Bowe: Employee; Self; Humana. M. Tindal: None. Y.A. Meah: None. P. Schwab: Employee; Self; Humana. Employee; Spouse/Partner; Humana.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
36-OR: Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists
This retrospective cohort study compared sodium-glucose co-transporter-2 (SGLT2) inhibitor and glucagon-like peptide-1 (GLP-1) agonist therapeutic drug classes on cardiovascular (CV) outcomes, treatment persistence/discontinuation, healthcare utilization and costs. Using medical and pharmacy claims data from the Humana Research Database, new users of SGLT2 inhibitors or GLP-1 agonists from January 2015 to June 2017 were identified. Eligible patients were 19-89 years, enrolled in a Medicare Advantage Prescription Drug or fully-insured commercial health plan, with at least 12 months of continuous enrollment pre- and post-index date (i.e., date of first new prescription). Propensity score matching (1:1) was used to balance baseline characteristics. Cox proportional hazards models were used to compare CV outcomes and treatment discontinuation. Healthcare resource utilization and costs were compared using Wilcoxon signed rank test. A total of 5,507 patients were included in each treatment group. Patients indexed to use GLP-1 agonists were more likely to discontinue treatment (hazard ratio 1.15, 95% confidence interval 1.10-1.21) and more likely to encounter an inpatient hospitalization (14.4% vs. 11.9%, P<0.001) or emergency department visit (27.4% vs. 23.5%, P <0.001) compared to patients indexed on SGLT2 inhibitors. The risk of primary composite CV outcome (myocardial infarction or stroke or mortality) and secondary CV outcome (heart failure or death) was similar across cohorts. The average per-person per-month total cost ($1,796 vs. $1,617, P<0.001), medical ($904 vs. $834, P<0.001) and pharmacy costs ($891 vs. $783, P<0.001) were higher for the GLP-1 agonist cohort compared to the SGLT2 inhibitor cohort. Although differences in extra-glycemic CV benefits were not established, these findings may be useful to providers and payers, as this real-world data showed SGLT2 inhibitors were associated with longer treatment persistence and reduced healthcare utilization and costs relative to GLP-1 agonists. Disclosure: I. Poonawalla: None. A. Bowe: Employee; Self; Humana. M. Tindal: None. Y.A. Meah: None. P. Schwab: Employee; Self; Humana. Employee; Spouse/Partner; Humana.
- Open Access
- 25 January 2016
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 18 (1) , e19
Impact of a Mobile Phone Intervention to Reduce Sedentary Behavior in a Community Sample of Adults: A Quasi-Experimental Evaluation
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- 25 January 2016
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 18 (1) , e19
Open AccessImpact of a Mobile Phone Intervention to Reduce Sedentary Behavior in a Community Sample of Adults: A Quasi-Experimental Evaluation
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- 1 October 2014
- Published by Elsevier in Addictive Behaviors
- Vol. 39 (10) , 1383-1388
Family income trajectory during childhood is associated with adolescent cigarette smoking and alcohol use
- 1 October 2014
- Published by Elsevier in Addictive Behaviors
- Vol. 39 (10) , 1383-1388
Family income trajectory during childhood is associated with adolescent cigarette smoking and alcohol use
- 1 March 2014
- Published by Elsevier in Addictive Behaviors
- Vol. 39 (3) , 717-720
Small financial incentives increase smoking cessation in homeless smokers: A pilot study
- 1 March 2014
- Published by Elsevier in Addictive Behaviors
- Vol. 39 (3) , 717-720
Small financial incentives increase smoking cessation in homeless smokers: A pilot study